Drug Profile
LY 3127760
Alternative Names: LY-3127760Latest Information Update: 11 Apr 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 18 Oct 2013 Phase-I clinical trials in Undefined indication (in volunteers) in USA (PO)